Diffuse Cutaneous Scleroderma (DSSc) SFDI Study

NANot yet recruitingINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Systemic SclerodermaDiffuse Cutaneous Scleroderma
Interventions
OTHER

Spatial-frequency domain imaging (SFDI)

SFDI is a method using near-infrared (NIR) light to generate wide field images (\>10 x 10 cm) of tissue optical properties (absorption and scattering coefficients) at sub-surface depths of 1-10 mm. With SFDI the tissue surface (skin) is illuminated by a rapid sequence of sinusoidal light patterns of varying spatial frequency and at different optical wavelengths. Collected camera images are then processed to yield maps of sub-surface optical properties.

Trial Locations (1)

02118

Shapiro Outpatient Rheumatology Clinic at Boston Medical Center, Boston

All Listed Sponsors
collaborator

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NIH

lead

Boston University

OTHER

NCT07090226 - Diffuse Cutaneous Scleroderma (DSSc) SFDI Study | Biotech Hunter | Biotech Hunter